Related Experiment Video
Updated: Jul 18, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
High-dose-rate brachytherapy for small-sized peripherally located lung cancer
Fumio Imamura1, Kiyonobu Ueno, Yoko Kusunoki
1Department of Pulmonary Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. imamura-fu@mc.pref.osaka.jp
Summary
High-dose-rate brachytherapy using an Iridium-192 source shows promise for treating early-stage non-small cell lung cancer (NSCLC). This minimally invasive approach achieved an 88.9% local control rate in peripheral NSCLC patients.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Increasing demand for minimally invasive treatments for early-stage non-small cell lung cancer (NSCLC).
- Peripheral NSCLC presents unique treatment challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of high-dose-rate brachytherapy for peripheral T1-2 N0 M0 NSCLC.
- To assess local control and survival rates.
Main Methods:
- Twelve patients with peripheral T1-2 N0 M0 NSCLC were treated with high-dose-rate brachytherapy using an Iridium-192 ((192)Ir) source.
- Treatments included percutaneous brachytherapy (single fraction of 20 Gy) and transbronchial brachytherapy (hypofractionated doses).
Main Results:
- Local control rate was 88.9% for brachytherapy as a primary treatment in T1 N0 M0 NSCLC.
- Estimated 5-year survival rates ranged from 60% to 70%.
- Complications were generally mild, with focal radiation pneumonitis observed in most patients.
Conclusions:
- High-dose-rate brachytherapy is a potential minimally invasive treatment option for peripheral T1 N0 M0 NSCLC.
- Further research is warranted to optimize treatment protocols and long-term outcomes.
